No abstract

The purpose of this study was to identify risk factors for hepatitis C virus (HCV) infection in a rural village in the Nile Delta with a high prevalence of antibodies to HCV (anti-HCV). One half of the village households were systematically selected, tested for anti-HCV, and interviewed: 973 of 3,999 (24.3%) subjects were anti-HCV-positive (reflecting prior HCV infection but not necessarily current liver disease), with nearly equal prevalence among males and females. Anti-HCV prevalence increased sharply with age among both males and females, from 9.3% in those 20 years of age and younger to >50% in those older than 35, suggesting a cohort effect with reduced transmission in recent years. Multivariate regression was used to estimate independent effects of risk factors on seropositivity. Among those over 20 years of age, the following risk factors were significantly associated with seropositivity: age (P < . Previous studies of hepatitis C viral (HCV) infection in Egypt have shown a high prevalence of antibody to HCV (anti-HCV) among blood donors 1-4 and residents of rural areas endemic for schistosomiasis. 5 Anti-HCV was found in 12.1% of primary schoolchildren, 18.1% of residents of rural villages, and 22.1% of army recruits, 6 as well as in 31% of Egyptians applying to work abroad. 7,8 It is widely believed that parenteral exposure to the virus is the most important route for acquiring infection in Egypt. 7,9 We have recently reported data that suggest the very high prevalence of HCV infection in the adult population of rural areas of Egypt, particularly in men living in villages where schistosomiasis is endemic, is at least partially the result of extensive mass-control campaigns using parenteral tartar emetic conducted from the 1950s up until 1982. 10 Although the prevalence of infection among those too young to be exposed to these mass antischistosomiasis injection campaigns is lower than among the older population, infection in this younger cohort indicates that other modes of transmission have perpetuated the infection in the community. Uncertainty remains regarding the relative importance of various types of parenteral exposures and widely practiced community activities, e.g., circumcisions, goza smoking in a group, or being shaved at a community barber.To resolve this uncertainty, we conducted a large serologic survey in a rural Egyptian community. The purpose of this article is to report the observed associations of HCV infection with both the acknowledged parenteral exposures (e.g., blood transfusions, injections, invasive hospital procedures, dental treatment) and widely practiced community activities that are usually not considered to be determinants of HCV transmission. PATIENTS AND METHODSStudy Population. In 1997, one half of the households of a village in the Nile Delta, Aghour El Soughra, were systematically selected and interviewed with a structured questionnaire to identify potential exposures that might be related to HCV acquisition. Adults and children older than 10 years of age were interv...

The epidemiology of hepatitis E virus (HEV), an enterically-transmitted cause of acute viral hepatitis (AVH), is not fully understood. During outbreaks on the Indian subcontinent and elsewhere, HEV causes severe AVH with mortality rates around 20% during pregnancy. In Egypt, where prevalence of HEV antibodies (anti-HEV) in rural communities is very high, severe HEV-caused AVH in pregnant women has not been reported. This study examined a cohort of 2,428 pregnant women in the Nile Delta to assess prevalence of, and risk factors for, anti-HEV and correlated these with history of liver disease. Anti-HEV prevalence was 84.3%. Several risk factors associated with anti-HEV included older age, many siblings, not using soap to wash produce and frequent contact with cats. History of jaundice and liver disease was rare and not increased in those having anti-HEV. Our results confirm Egypt's high HEV endemicity and show that almost all women of childbearing age in these communities had prior HEV exposures without a history of liver disease. Reasons for the lack of clinical hepatitis remain unclear but could be the result of early childhood HEV exposures, producing long-lasting immunity and/or modify subsequent responses to exposure. Alternatively, the predominant HEV strain(s) in Egypt are less virulent than those in South Asia.

In Egypt, schistosomiasis was traditionally the most important public health problem and infection with Schistosoma mansoni the major cause of liver disease. From the 1950s until the 1980s, the Egyptian Ministry of Health (MOH) undertook large control campaigns using intravenous tartar emetic, the standard treatment for schistosomiasis, as community-wide therapy. This commendable effort to control a major health problem unfortunately established a very large reservoir of hepatitis C virus (HCV) in the country. By the mid-1980s, the effective oral drug, praziquantel, replaced tartar emetic as treatment for schistosomiasis in the entire country. This both reduced schistosomal transmission and disease and interrupted the "occult" HCV epidemic. It was evident when diagnostic serology became available in the 1990s that HCV had replaced schistosomiasis as the predominant cause of chronic liver disease. Epidemiological studies reported a high prevalence and incidence of HCV, particularly within families in rural areas endemic for schistosomiasis. Clinical studies showed 70% to 90% of patients with chronic hepatitis, cirrhosis, or hepatocellular carcinoma had HCV infections. Co-infections with schistosomiasis caused more severe liver disease than infection with HCV alone. Schistosomiasis was reported to cause an imbalance in HCV-specific T-cell responses leading to increased viral load, a higher probability of HCV chronicity, and more rapid progression of complications in co-infected persons. As complications of HCV usually occur after 20 years of infection, the peak impact of the Egyptian outbreak has not yet occurred. Efforts have been initiated by the Egyptian MOH to prevent new infections and complications of HCV in the estimated 6 million infected persons. (HEPATOLOGY 2006;43:915-922.)